首页> 外文期刊>Microbiology and Immunology >Development and characterization of a catalytically inactive cysteine protease domain of RtxA1/MARTX(Vv) as a potential vaccine for Vibrio vulnificus
【24h】

Development and characterization of a catalytically inactive cysteine protease domain of RtxA1/MARTX(Vv) as a potential vaccine for Vibrio vulnificus

机译:RtxA1 / MARTX(Vv)的无催化活性的半胱氨酸蛋白酶结构域的开发和表征,作为潜在的创伤弧菌疫苗

获取原文
获取原文并翻译 | 示例
           

摘要

Recent studies have defined several virulence factors as vaccine candidates against Vibrio vulnificus. However, most of these factors have the potential to cause pathogenic effects in the vaccinees or induce incomplete protection. To overcome these drawbacks, a catalytically inactive form, CPDVv(C3725S), of the well-conserved cysteine protease domain (CPD) of V. vulnificus multifunctional autoprocessing repeats-in-toxin (MARTX(Vv)/RtxA1) was recombinantly generated and characterized. Notably, active and passive immunization with CPDVv(C3725S) conferred protective immunity against V. vulnificus strains. These results may provide a novel framework for developing safe and efficient subunit vaccines and/or therapeutics against V. vulnificus that target the CPD of MARTX toxins.
机译:最近的研究已经确定了几种毒力因子作为针对创伤弧菌的候选疫苗。但是,大多数这些因素都有可能在疫苗中引起致病作用或诱导不完全的保护。为了克服这些缺点,重组生成了伏氏弧菌多功能自加工毒素重复序列(MARTX(Vv)/ RtxA1)​​的保守性很强的半胱氨酸蛋白酶结构域(CPD)的催化失活形式CPDVv(C3725S) 。值得注意的是,用CPDVv(C3725S)进行的主动和被动免疫可赋予针对V. vulnificus菌株的保护性免疫力。这些结果可以为开发针对MARTX毒素的CPD的针对V.vulnificus的安全有效的亚单位疫苗和/或疗法提供新颖的框架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号